Sotera Health stock
SHCNASDAQSotera Health Company, HealthcareISIN US83601L1026
55Score 55 out of 100, Neutral
Price and trend
52 / 100
Price history
+0.3% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 3.5% below it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 33).
The price is 17% below its 52-week high. Largest decline in 6 years: 79% (March 2021 to November 2022).
Chart figures for advanced users
- SMA 50$18.01
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$16.89
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)33
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$13.13
- The lowest closing price of the last twelve months.
- Resistance$19.57
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Sotera Health Company belongs to the Medical (Diagnostics & Research) industry (United States) and, with a market value of $4.65B, is number 26 of 37 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.16B (up 5.7% year on year) and earnings of $77.95M (up 75.6%).
- For fiscal 2026, analysts expect on average revenue of $1.24B (up 6.9%) and adjusted earnings per share of $0.98 (up 14.4%).
Show more
- MEQIRI Score 55 out of 100 (Neutral): rank 338 of 714 in Healthcare, median 53.
- The P/E is 27.2 (Medical (Diagnostics & Research) median 33.7, own median of recent years 75.4).
- Our model puts fair value at $15.40, with the price 7% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- High debtDebt 3.1 times equity (latest quarter), Medical (Diagnostics & Research) median 0.48.Stability 43
- Interest barely coveredOperating profit covers interest only 1.9 times.Stability 43
The score is held back by capital allocation and stability.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
Valuation
Valuation signal
Fairly valuedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $11.85 and expensive above $22.01 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $10.57 (cash-flow model) and $20.24 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 10.9%. At 11.9% the fair value would be $14.69, at 9.9% it would be $16.36.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (33.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 6.9% on the twelve months before. Revenue has grown solidly since 2018, at about 7% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 55%, operating 34%, net 7%. Last 12 months: net 14%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 23 Feb 2027in 103 days
- Last reported
- 3 Nov 2026EPS reported $0.29 (expected $0.27)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $0.980.0%
- Revenue
- $1.24B−0.2%
- Earnings per share
- $1.07−0.9%
- Revenue
- $1.31B−0.6%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +4.9%2026 outlook raised: revenue of $1.236 billion to $1.254 billion (5.25% to 6.75% growth), adjusted EPS of $0.95 to $1.01 versus $0.93 to $1.01.
“We now expect total company revenue to grow to a range of $1.236 billion to $1.254 billion, representing 5.25% to 6.75% constant currency growth and an estimated 100 basis point foreign currency benefit.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 4 insiders sold, $506.92M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Petras Michael B. Jr.Sale
17 Aug 2026, Executive Chairman
- Shares
- 1,144,515
- Price
- $18.50
- Value
- $21.17M
- Rutz Michael PSale
7 Aug 2026, President of Sterigenics
- Shares
- 150,000
- Price
- $18.84
- Value
- $2.83M
- Warburg Pincus & Co.Sale
13 May 2026, Board
- Shares
- 19,102,952
- Price
- $15.17
- Value
- $289.75M
Show 1 more
- Gtcr Investment Xi LlcSale
13 May 2026, Board
- Shares
- 12,735,301
- Price
- $15.17
- Value
- $193.17M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Sotera Health
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 55
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Diagnostics & Research)
The next larger and next smaller companies by market value
- RadNetRDNT $6.14B44
- GRAILGRAL $5.65B43
- BillionToOneBLLN $5.27B64
- DiaSorinDIA.MI $5.14B67
- CareDxCDNA $4.26B59
- Vimian GroupVIMIAN.ST $2.23B58
- NeoGenomicsNEO $2.19B40
- VeracyteVCYT $2.03B53
ETFs that hold Sotera Health
Held by 10 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY4 | 0.14% | 0.30% | €5.27B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.06% | 0.43% | €2.48B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.04% | 0.35% | €8.19B |
Show 5 more
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.04% | 0.30% | €944.34M |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.01% | 0.25% | €175.89M |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.35% | €434.1M |
| Vanguard ESG Global All Cap UCITS ETF (USD) AccumulatingV3AA | 0.01% | 0.24% | €1.69B |
| Vanguard FTSE Global All-Cap UCITS ETF Accum USDVGLA | 0.00% | 0.07% | €3.9B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 20 Feb 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.